Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways

19 Apr 2022

Abstract excerpt

The clinical introduction of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, which targets B-cell antigen-receptor (BCR)-controlled integrin-mediated retention of malignant B cells in their growth-supportive lymphoid organ microenvironment, provided a major breakthrough in lymphoma and leukemia treatment. Unfortunately, a significant subset of patients is intrinsically resistant or acquires resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research
Share to Immunodeficiency and Autoimmune Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35440579
DOI: 10.1038/s41467-022-29835-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathwaysPMID 35440579Read ↗

Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.Semantic proximity Read ↗

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell MalignanciesSemantic proximity Read ↗

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphomaSemantic proximity Read ↗

ANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library.Semantic proximity Read ↗

Gene editing of BTK using CRISPR/Cas9 to study drug resistance in acute myeloid leukaemiaSemantic proximity Read ↗

A CRISPR screen targeting PI3K effectors identifies RASA3 as a negative regulator of LFA-1–mediated adhesion in T cellsSemantic proximity Read ↗

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read ↗

Kindlin-2 Regulates the Oncogenic Activities of Integrins and TGF-β In Triple Negative Breast Cancer Progression and MetastasisSemantic proximity Read ↗

Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesotheliomaSemantic proximity Read ↗

Integrin-linked kinase – essential roles in physiology and cancer biologySemantic proximity Read ↗

Targeting the integrin interactome in human diseaseSemantic proximity Read ↗

Role of Bruton’s tyrosine kinase in B cells and malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.